论文部分内容阅读
[目的]评价β-榄香烯乳联合肝动脉化疗栓塞(TACE)治疗中晚期肝癌的疗效。[方法]入组42例中晚期肝癌患者随机分为联合组(n=21)和对照组(n=21)。对照组仅行TACE治疗,联合组行肝动脉灌注β-榄香烯乳联合TACE治疗。比较两组疗效、生存情况。[结果]联合组有效率明显优于对照组(57.1%vs 28.6%,P=0.032)。对照组和联合组中位无进展生存期(PFS)分别为131d和183d(P=0.011),中位生存时间(MST)分别为230d和253d(P=0.096)。两组均未出现严重的不良反应,联合组腹痛较对照组轻(P=0.039)。[结论]β-榄香烯乳联合TACE治疗中晚期肝癌可提高疗效,且不良反应可耐受。
[Objective] To evaluate the efficacy of β-elemene combined with transcatheter arterial chemoembolization (TACE) in the treatment of advanced liver cancer. [Methods] 42 patients with advanced hepatocellular carcinoma were randomly divided into the combined group (n = 21) and the control group (n = 21). The control group only TACE treatment, the combined group of hepatic arterial infusion of β-elemene combined with TACE treatment. Compare the two groups efficacy and survival. [Results] The combined group was significantly better than the control group (57.1% vs 28.6%, P = 0.032). Median progression-free survival (PFS) was 131 and 183 days in the control group and the combined group (P = 0.011). The median survival time (MST) was 230 days and 253 days, respectively (P = 0.096). No serious adverse reactions occurred in both groups, and the abdominal pain in the combination group was lighter than that in the control group (P = 0.039). [Conclusion] β-elemene combined with TACE in the treatment of advanced hepatocellular carcinoma can improve the curative effect, and the adverse reaction can be tolerated.